Quantitative systems pharmacology: Landscape analysis of regulatory submissions to the US Food and Drug Administration

被引:36
|
作者
Bai, Jane P. F. [1 ]
Earp, Justin C. [1 ]
Florian, Jeffry [1 ]
Madabushi, Rajanikanth [1 ]
Strauss, David G. [1 ]
Wang, Yaning [1 ]
Zhu, Hao [1 ]
机构
[1] US FDA, Off Clin Pharmacol, Ctr Drug Evaluat & Res, Silver Spring, MD USA
来源
关键词
D O I
10.1002/psp4.12709
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Quantitative systems pharmacology (QSP) has been proposed as a scientific domain that can enable efficient and informative drug development. During the past several years, there has been a notable increase in the number of regulatory submissions that contain QSP, including Investigational New Drug Applications (INDs), New Drug Applications (NDAs), and Biologics License Applications (BLAs) to the US Food and Drug Administration. However, there has been no comprehensive characterization of the nature of these regulatory submissions regarding model details and intended applications. To address this gap, a landscape analysis of all the QSP submissions as of December 2020 was conducted. This report summarizes the (1) yearly trend of submissions, (2) proportion of submissions between INDs and NDAs/BLAs, (3) percentage distribution along the stages of drug development, (4) percentage distribution across various therapeutic areas, and (5) nature of QSP applications. In brief, QSP is increasingly applied to model and simulate both drug effectiveness and safety throughout the drug development process across disease areas.
引用
收藏
页码:1479 / 1484
页数:6
相关论文
共 50 条
  • [21] A year in pharmacology: new drugs approved by the US Food and Drug Administration in 2020
    Kayki-Mutlu, Gizem
    Michel, Martin C.
    NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY, 2021, 394 (05) : 839 - 852
  • [22] A year in pharmacology: new drugs approved by the US Food and Drug Administration in 2020
    Gizem Kayki-Mutlu
    Martin C. Michel
    Naunyn-Schmiedeberg's Archives of Pharmacology, 2021, 394 : 839 - 852
  • [23] A year in pharmacology: new drugs approved by the US Food and Drug Administration in 2023
    Gizem Kayki-Mutlu
    Zinnet Sevval Aksoyalp
    Leszek Wojnowski
    Martin C. Michel
    Naunyn-Schmiedeberg's Archives of Pharmacology, 2024, 397 : 2949 - 2970
  • [24] US Food and Drug Administration regulatory updates in neuro-oncology
    Mehta, Gautam U.
    Barone, Amy K.
    Bradford, Diana
    Larkins, Erin
    Kim, Janice
    Pai-Scherf, Lee
    Jaigirdar, Adnan
    Shah, Mirat
    Wedam, Suparna
    Amiri-Kordestani, Laleh
    Theoret, Marc R.
    Pazdur, Richard
    Beaver, Julia A.
    Singh, Harpreet
    JOURNAL OF NEURO-ONCOLOGY, 2021, 153 (03) : 375 - 381
  • [25] The clinical pharmacogeneticist: An emerging regulatory scientist at the US Food and Drug Administration
    Issam Zineh
    Janet Woodcock
    Human Genomics, 4 (4)
  • [26] US Food and Drug Administration - A science-based regulatory agency
    Schwetz, BA
    JOURNAL OF AOAC INTERNATIONAL, 2001, 84 (01) : 171 - 175
  • [27] US Food and Drug Administration regulatory approaches for xenotransplantation products and xenografts
    Arcidiacono, Judith
    XENOTRANSPLANTATION, 2020, 27 (06) : CP5 - U7
  • [28] A year in pharmacology: new drugs approved by the US Food and Drug Administration in 2022
    Gizem Kayki-Mutlu
    Zinnet Sevval Aksoyalp
    Leszek Wojnowski
    Martin C. Michel
    Naunyn-Schmiedeberg's Archives of Pharmacology, 2023, 396 : 1619 - 1632
  • [29] US Food and Drug Administration regulatory updates in neuro-oncology
    Gautam U. Mehta
    Amy K. Barone
    Diana Bradford
    Erin Larkins
    Janice Kim
    Lee Pai-Scherf
    Adnan Jaigirdar
    Mirat Shah
    Suparna Wedam
    Laleh Amiri-Kordestani
    Marc R. Theoret
    Richard Pazdur
    Julia A. Beaver
    Harpreet Singh
    Journal of Neuro-Oncology, 2021, 153 : 375 - 381
  • [30] Regulatory review intervals for ophthalmic new drug applications at the US food and drug administration
    Novack, GD
    AMERICAN JOURNAL OF OPHTHALMOLOGY, 1998, 126 (01) : 122 - 126